Sandoz Group AG

Equities

SDZ

CH1243598427

Pharmaceuticals

Market Closed - Swiss Exchange 11:31:30 2024-04-26 am EDT 5-day change 1st Jan Change
30 CHF -2.31% Intraday chart for Sandoz Group AG +1.66% +10.86%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cigna to offer Humira rivals with $0 copay at specialty pharmacy RE
Swiss Market Index Closes Higher; UBS Slumps MT
Sandoz Upgrades Sandoz to Buy from Neutral, Boosts PT MT
Sandoz: boosted by broker upgrade CF
SANDOZ : UBS raises its recommendation CF
Sandoz: approval of Pyzchiva in Europe CF
European Commission Grants Marketing Authorization for Sandoz Biologic Therapy Pyzchiva MT
Sandoz Confirms European Commission Approval of Pyzchiva® (ustekinumab), Further Strengthening Immunology Offering CI
Bausch wins US appeal to block Alvogen generic of diarrhea drug RE
Boehringer to lay off salespeople as Humira biosimilar sales lag RE
Boehringer to lay off salespeople as Humira biosimilar sales lag RE
Swiss Certification Company SGS Names Sandoz Chief Accounting Officer as New CFO MT
Sandoz: new production site in Kundl CF
Sandoz Launches New Antibiotic Production Plant in Kundl, Austria MT
Sandoz Group Opens New Antibiotic Production Facility in Kundl, Austria MT
Sandoz Opens New Production Facility in Kundl, Austria to Significantly Increase Capacity for Life-Saving Medicines CI
SANDOZ : Stifel raises target price CF
Swiss Stocks Extend Rally Amid Earnings Buzz MT
Global markets live: Adidas, EON, Sandoz, Bayer, Boeing... Our Logo
SANDOZ : Noteworthy progress on the areas for improvement Alphavalue
Sandoz: two treatments approved by the US FDA CF
Sandoz core EPS down 22% in 2023 CF
Transcript : Sandoz Group AG, Q4 2023 Earnings Call, Mar 13, 2024
Sandoz Posts Drop in FY23 Core Net Income, Sales Rise MT
Sandoz Group AG Recommends Dividend CI
Chart Sandoz Group AG
More charts
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
32.8 USD
Average target price
38.49 USD
Spread / Average Target
+17.36%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. SDZ Stock
  4. News Sandoz Group AG
  5. Swiss Stocks Extend Rally Amid Earnings Buzz